Mar 25, 2011
From the Healthcare & Life Sciences Institute
An Overview of Risk and Disclosure, which is a summary of our Disclosures Handbook 2009-2010, provides key points of the Handbook and an overview of Risk and Disclosure in the Pharma Industry.
The Disclosures Handbook 2009-2010 analyzes trends in financial reporting across the industry and provides insights from KPMG partners and managers around the world. Our analysis of 2009 financial reporting data for the largest global pharmaceutical companies shows an increase in reporting risks related to strategic alliances and drug development spending, and limited R&D investment. The industry is shifting towards a more challenging cost-oriented environment amid continuing demand for more innovative medicines.